Orexo AB – Financial calendar 2007

Orexo AB (publ) today announced the following preliminary dates for the release of its quarterly reports and the Annual General Meeting in 2007:

Q4 2006, Full Year Report 2006 – February 20, 2007
Q1 2007, Interim Report January – March 2007 – May 9, 2007
Q2 2007, Interim Report January – June 2007 – August 14, 2007
Q3 2007, Interim Report January – September 2007 – November 6, 2007

Annual General Meeting (Stockholm) – April 23 at 17.00.

For more information, please contact
Claes Wenthzel, Executive Vice President and CFO, Orexo AB
+46 (0)18 780 88 44, +46 (0)708-62 01 22, e-mail: claes.wenthzel@orexo.se

About Us

Orexo develops improved pharmaceuticals based on innovative drug delivery technologies.The focus is primarily on opioid dependence and pain but the aim is to address therapeutic areas where our competence and technologies can create value. The main market today is the US market for the treatment of opioid dependence where the product Zubsolv® is commercialized by Orexo. Other products are commercialized by license partners, including Zubsolv in markets outside of the US. Total net sales for 2016 amounted to SEK 705.9 million and the number of employees was 102. Orexo is listed on the Nasdaq Stockholm Mid Cap (ORX) index and is available as ADRs on OTCQX (ORXOY) in the US. The head office, where also research and development is performed, is located in Uppsala, Sweden.


Documents & Links